Biotech stocks are dominating today's unusual options volume list, with United Therapeutics Corporat

Corient Private Wealth LP reduced its holdings in United Therapeutics Corporation (NASDAQ: UTHR) by

United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 sh

United Therapeutics Corporation (UTHR) Presents at Morgan Stanley 24th Annual Global Healthcare Conf

United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 sh

United Therapeutics (NASDAQ: UTHR - Get Free Report) and Zenas BioPharma (NASDAQ: ZBIO - Get Free Re

United Therapeutics Corporation (UTHR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare C

United Therapeutics Corporation (UTHR) Presents at Wells Fargo 21st Annual Healthcare Conference Tra

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation

Hsbc Holdings PLC grew its position in United Therapeutics Corporation (NASDAQ: UTHR) by 6.6% in the

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?

FDA accepts United Therapeutics' Tyvaso sNDA for an IPF label expansion, backed by TETON data showin

Healthcare stocks UTHR, COLL and AHG show oversold RSI levels near or below 30, potentially offering

Nebulized Tyvaso® (treprostinil) Inhalation Solution will be the first and only inhaled anti-fibroti

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation

Canada Pension Plan Investment Board bought a new position in United Therapeutics Corporation (NASDA

Freestone Grove Partners LP bought a new position in United Therapeutics Corporation (NASDAQ: UTHR)

Corient Private Wealth LP purchased a new stake in United Therapeutics Corporation (NASDAQ: UTHR) in

UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data

ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvem

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that f

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C--(BUSINESS WIRE)--United Therapeutics Corporation (

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation

Approximately 200,000 patients in the United States have PPF, with limited treatment optionsTopline

RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and

The long-term, pivotal, phase 3 ADVANCE OUTCOMES study of ralinepag in predominantly pre-treated pat

JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and r

B of A Securities analyst Greg Harrison maintains United Therapeutics (NASDAQ:UTHR) with a Neutra

The flights carried manufactured organs, being developed by United TherapeuticsThe flights are also

RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and

United Therapeutics (UTHR) acquires Thymmune Therapeutics for $140M upfront, with up to $160M in mil

United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics

United Therapeutics received FDA approval for LungFX, a device designed to expand donor lung use in

The pivotal TETON-1 phase 3 study of nebulized Tyvaso® (treprostinil) Inhalation Solution in idiopat

U.S. stock futures down on Monday. Focus on Baidu, Brady, United Therapeutics for earnings. XP and R

United Therapeutics Corporation (NASDAQ:UTHR), a public benefit corporation, today announced that th

Through the collaboration, Varda and United Therapeutics will conduct pharmaceutical processing of s

Presentations of results from the positive TETON phase 3 pivotal studies of inhaled treprostinil in

RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and

Wells Fargo analyst Benjamin Burnett upgrades United Therapeutics (NASDAQ:UTHR) from Equal-Weight

The formulation is being developed in collaboration with United Therapeutics Corporation United Ther

United Therapeutics (NASDAQ:UTHR) reported quarterly earnings of $5.82 per share which missed the an

An interim analysis of the PHINDER study identifies non-invasive measures that may facilitate earlie

Morgan Stanley analyst Terence Flynn maintains United Therapeutics (NASDAQ:UTHR) with a Equal-Wei

HC Wainwright & Co. analyst Andrew S. Fein maintains United Therapeutics (NASDAQ:UTHR) with a

Wells Fargo analyst Benjamin Burnett maintains United Therapeutics (NASDAQ:UTHR) with a Equal-Wei

B of A Securities analyst Greg Harrison maintains United Therapeutics (NASDAQ:UTHR) with a Neutra